Practice open cooperation and promote pharmaceutical innovation: Sanofi and Suzhou Institute of systems medicine jointly held a seminar on innovative drugs

      In order to promote exchanges in this field, Sanofi Asia Pacific R & D headquarters and the center for systems medicine of the Chinese Academy of Medical Sciences and Suzhou Institute of systems medicine recently jointly held a seminar on innovative drugs More than 100 scientists, researchers and representatives of biotechnology enterprises attended the conference to share cutting-edge discoveries in the field of biomedicine and translational medicine, especially in immunology , infectious diseases, oncology and other fields of the latest research results Dr Elias Zerhouni, President of Sanofi global R & D, and Dr Elias Zerhouni, President of Sanofi global R & D delivered an opening speech on behalf of the company As a supporter and advocate of translational medicine, Dr Zeng Heli said that translational medicine is not only of strategic significance for building a healthy China, but also one of Sanofi's important strategies, which runs through the entire R & D industry chain of the company Sanofi is implementing strategic transformation to meet the medical needs of patients in the fastest and most effective way Cooperation with leading research institutions in the industry, including Suzhou Institute of systems medicine, will help to establish an effective communication platform and promote the transformation of scientific research findings into innovative medical solutions The emergence of breakthrough innovative drugs not only requires a deep understanding of the complexity of human biology, but also requires the full cooperation of biotechnology enterprises, research institutions and the vast number of scientific research and medical units The combination of production, education and research is the most effective way to accelerate drug innovation and benefit patients Dr Zhang Yu, chief scientific officer of Sanofi Asia Pacific R & D headquarters and President of China R & D center, analyzed that it is one of Sanofi Asia Pacific R & D strategies to deeply develop the ecosystem and grasp the local R & D opportunities Sanofi has established more than 60 cooperative R & D projects in the Asia Pacific region, and through cooperation with top research institutions such as the Pasteur Institute of the Chinese Academy of Sciences and the Shanghai Institute of life sciences, it has jointly expanded research in frontier fields With the further expansion of global medical research cooperation, China has gradually become one of the most dynamic and potential areas in the field of biomedical research "As a Chinese scientist, I'm very glad to see that China's scientific research level is improving day by day and has made a series of breakthroughs in the field of basic research," said Dr Liu Yongjun, head of Sanofi's global research department Sanofi also strives to connect the local scientific research achievements with the innovative thinking of our global R & D ecosystem and double the efficiency of R & D We look forward to cooperating with more local first-class scientific research institutions, giving full play to the innovation capacity of Asia Pacific, and bringing innovative drugs to patients better and faster " Cheng genhong, director of Suzhou Institute of systematic medicine, echoed that he would fully support the initiative of open cooperation and jointly promote the process of pharmaceutical innovation.